Synthesis and photoluminescence studies on catalytically grown Zn1 – xMnxS nanowires

Zn1 – xMnxS alloy nanowires with composition (x = 0.0, 0.1 and 0.3) have been successfully synthesized by a simple thermal evaporation on the silicon substrate coated with a gold film of 2 nm thickness. X-ray powder diffraction measurements reveal that as synthesized products were hexagonal wurtzite structure. The as grown nanowires have been investigated by Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), Energy Dispersive Analysis of X-rays (EDAX) and photoluminescence studies. The results reveal that the as grown nanowires consist of Zn, Mn, and S material and diameter ranging from 70 - 150 nm with lengths up to several tens of micrometers. Photoluminescence studies on Zn1 – xMnxS exhibited peaks at 600 and 613 nm for x = 0.1 and 0.3 respectively. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/1053

Fabrication Of ZnxCd1 – xSe Nanowires By CVD Process And Photoluminescence Studies

ZnxCd1 – xSe alloy nanowires with composition x = 0.2, 0.5 have been successfully synthesized by a simple thermal evaporation on the silicon substrate coated with a gold film of 20 Å thickness. The as-synthesized alloy nanowires, 70 - 150 nm in diameter and several tens of micrometer in length. The nanowires are single crystalline revealed from Transmission electron microscopy (TEM) and XRD measurement. The structure of ZnxCd1 – xSe nanowires are hexagonal wurtzite with [01-10] growth direction. Energy gap of the ZnxCd1 – xSe nanowires are determined from micro photoluminescence measurements. The energy gap increases with increasing Zn concentration. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/954

Magnetic and dielectric properties of BiFeO3 nanoparticles

Single crystalline nano-sized multiferroic BiFeO3 (BFO) powders were synthesized through simple chemical co-precipitation method using polyethylene glycol (PEG) as capping agent. We obtained pure phase BiFeO3 powder by controlling pHand calcination temperature. From X-ray diffraction studies the nanoparticles were unambiguously identified to have a rhombohedrally distorted perovskite structure belonging to the space group of R3c. No secondary phases were detected. It indicates single phase structure. EDX spectra indicated the appearance of three elements Bi, Fe, O in 1:1:3. From the UV-Vis diffuse reflectance spectrum, the absorption cut-off wavelength of the BFO sample is around 558nm corresponding to the energy band gap of 2.2 eV. The size (60-70 nm) and morphology of the nanoparticles have been analyzed using transmission electron microscopy (TEM).   Linear M−H behaviour and slight hysteresis at lower magnetic field is observed for BiFeO3 nanoparticles from Vibrating sample magnetometer studies. It indicates weak ferromagnetic behaviour at room temperature. From dielectric studies, the conductivity value is calculated from the relation s = L/RbA Sm-1 and it is around 7.2 x 10-9 S/m

Effect of Mg Doping on the Structural and Optical Properties of CdS Nanoparticles Synthesized by co-Precipitation Method

Cd1 – xMgxS (x = 0.00, 0.05, 0.10, 0.15 and 0.20) nanoparticles were synthesized by co-precipitation method for the first time. Compositional, morphological, structural and optical studies of the as prepared samples were carried out by X-ray diffraction (XRD), Energy dispersive analysis of X-rays (EDAX), Scanning electron microscopy (SEM), Diffuse reflectance spectroscopy (DRS) and Photoluminescence (PL) techniques. XRD studies revealed the structural phase transition from cubic to hexagonal and increase in the average grain size of the nanoparticles (lie in the range 1.4 nm to 2.8 nm) with increasing Mg content. EDAX spectra rules out the existence of impurities in the samples. Bandgap widening was observed in all the samples compared to bulk CdS (2.42 eV). Decrease in bandgap (3.02 eV to 2.54 eV), luminescence quenching and red shift of luminescence peak position were observed with increasing Mg in Cd1 – xMgxS. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/3028

Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States: A Cost-Effectiveness Analysis

Background: The HIV Prevention Trials Network (HPTN) 083 trial demonstrated the superiority of long-acting injectable cabotegravir (CAB-LA) compared with oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP). Objective: To identify the maximum price premium (that is, greatest possible price differential) that society should be willing to accept for the additional benefits of CAB-LA over tenofovir-based PrEP among men who have sex with men and transgender women (MSM/TGW) in the United States. Design: Simulation, cost-effectiveness analysis. Data Sources: Trial and published data, including estimated HIV incidence (5.32, 1.33, and 0.26 per 100 person-years for off PrEP, generic F/TDF and branded emtricitabine–tenofovir alafenamide (F/TAF), and CAB-LA, respectively); 28% 6-year PrEP retention. Annual base-case drug costs: $360 and$16 800 for generic F/TDF and branded F/TAF. Fewer side effects with branded F/TAF versus generic F/TDF were assumed. Target Population: 476 700 MSM/TGW at very high risk for HIV (VHR). Time Horizon: 10 years. Perspective: Health care system. Intervention: CAB-LA versus generic F/TDF or branded F/TAF for HIV PrEP. Outcome Measures: Primary transmissions, quality-adjusted life-years (QALYs), costs (2020 U.S. dollars), incremental cost-effectiveness ratios (ICERs; U.S. dollars per QALY), maximum price premium for CAB-LA versus tenofovir-based PrEP. Results of Base-Case Analysis: Compared with generic F/ TDF (or branded F/TAF), CAB-LA increased life expectancy by 28 000 QALYs (26 000 QALYs) among those at VHR. Branded F/ TAF cost more per QALY gained than generic F/TDF compared with no PrEP. At 10 years, CAB-LA could achieve an ICER of at most $100 000 per QALY compared with generic F/TDF at a maximum price premium of$3700 per year over generic F/TDF (CAB-LA price <$4100 per year). Results of Sensitivity Analysis: In a PrEP-eligible population at high risk for HIV, rather than at VHR (n = 1 906 800; off PrEP incidence: 1.54 per 100 person-years), CAB-LA could achieve an ICER of at most$100 000 per QALY versus generic F/TDF at a maximum price premium of $1100 per year over generic F/TDF (CAB-LA price <$1500 per year). Limitation: Uncertain clinical and economic benefits of averting future transmissions. Conclusion: Effective oral PrEP limits the additional price society should be willing to pay for CAB-LA